These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30088308)

  • 1. Efficacy of sirolimus in an infant with Kasabach-Merritt phenomenon.
    Kumagai C; Ozeki M; Nozawa A; Kakuda H; Fukao T
    Pediatr Int; 2018 Sep; 60(9):887-889. PubMed ID: 30088308
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus.
    Tan X; Zhang J; Zhou S; Liu Z; Zhang T; Xia J
    J Dermatol; 2018 May; 45(5):580-583. PubMed ID: 29356076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Merit of Sirolimus for the Kasabach-Merritt Phenomenon.
    Heymann WR
    Skinmed; 2019; 17(6):394-395. PubMed ID: 31904330
    [No Abstract]   [Full Text] [Related]  

  • 4. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
    Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
    Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
    Wang H; Guo X; Duan Y; Zheng B; Gao Y
    Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.
    Wang Z; Li K; Dong K; Xiao X; Zheng S
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):72-3. PubMed ID: 24309604
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
    Chan S; Cassarino DS
    JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapamycin-associated lymphoedema in an infant with Kasabach-Merritt phenomenon.
    Boccara O; Hadj-Rabia S; Bourrat E; Coulombe J; Bodemer C
    Br J Dermatol; 2016 Apr; 174(4):933-4. PubMed ID: 26955901
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
    Ji Y; Chen S; Yang K; Xia C; Peng S
    J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of an mTOR Inhibitor in Kasabach-Merritt Phenomenon with Indolent Tufted Angioma: A Case Report.
    Nardin C; Boccara O; Eschard C; Bayaram M; Dabudyk T; Aubin F; Puzenat E
    Acta Derm Venereol; 2017 Jul; 97(7):851-852. PubMed ID: 27958609
    [No Abstract]   [Full Text] [Related]  

  • 11. Refractory Kasabach-Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work.
    Wang Z; Li K; Dong K; Xiao X; Zheng S
    J Dermatol; 2015 Apr; 42(4):401-4. PubMed ID: 25728547
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
    Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas.
    Ying H; Qiao C; Yang X; Lin X
    Pediatrics; 2018 Apr; 141(Suppl 5):S425-S429. PubMed ID: 29610165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus.
    Reichel A; Hamm H; Wiegering V; Wiewrodt B; Neubauer H; Ernestus K; Winkler B
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):329-331. PubMed ID: 28220608
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid response of Kasabach-Meritt phenomenon to a combination of oral prednisolone and sirolimus.
    Singh S; Bhari N; Agrawal S; Verma KK
    Indian J Dermatol Venereol Leprol; 2019; 85(3):348. PubMed ID: 29798936
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
    Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
    Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
    Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
    Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of a patient with Kasabach-Merritt syndrome and multiple giant hepatic hemangiomas.
    Liu Y; Wu X; Ye L; Xu H
    J Int Med Res; 2020 Jan; 48(1):300060519898358. PubMed ID: 31948308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of sirolimus on Kasabach-Merritt phenomenon coagulopathy.
    Boccara O; Puzenat E; Proust S; Leblanc T; Lasne D; Hadj-Rabia S; Bodemer C
    Br J Dermatol; 2018 Feb; 178(2):e114-e116. PubMed ID: 28796887
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.
    Fernandez-Pineda I; Lopez-Gutierrez JC; Chocarro G; Bernabeu-Wittel J; Ramirez-Villar GL
    Pediatr Blood Cancer; 2013 Sep; 60(9):1478-81. PubMed ID: 23609996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.